PROCTER & GAMBLE HEALTH | VENUS REMEDIES | PROCTER & GAMBLE HEALTH/ VENUS REMEDIES |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 34.4 | 15.4 | 223.0% | View Chart |
P/BV | x | 10.5 | 1.0 | 1,078.7% | View Chart |
Dividend Yield | % | 2.0 | 0.0 | - |
PROCTER & GAMBLE HEALTH VENUS REMEDIES |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
PROCTER & GAMBLE HEALTH Jun-23 |
VENUS REMEDIES Mar-23 |
PROCTER & GAMBLE HEALTH/ VENUS REMEDIES |
5-Yr Chart Click to enlarge
|
||
High | Rs | 5,366 | 379 | 1,416.1% | |
Low | Rs | 3,883 | 145 | 2,677.9% | |
Sales per share (Unadj.) | Rs | 740.7 | 415.5 | 178.3% | |
Earnings per share (Unadj.) | Rs | 138.2 | 19.9 | 695.7% | |
Cash flow per share (Unadj.) | Rs | 155.2 | 44.0 | 352.4% | |
Dividends per share (Unadj.) | Rs | 95.00 | 0 | - | |
Avg Dividend yield | % | 2.1 | 0 | - | |
Book value per share (Unadj.) | Rs | 447.6 | 344.3 | 130.0% | |
Shares outstanding (eoy) | m | 16.60 | 13.37 | 124.2% | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 6.2 | 0.6 | 990.4% | |
Avg P/E ratio | x | 33.5 | 13.2 | 253.8% | |
P/CF ratio (eoy) | x | 29.8 | 5.9 | 501.0% | |
Price / Book Value ratio | x | 10.3 | 0.8 | 1,358.1% | |
Dividend payout | % | 68.7 | 0 | - | |
Avg Mkt Cap | Rs m | 76,761 | 3,501 | 2,192.2% | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 2,062 | 570 | 361.4% | |
Avg. sales/employee | Rs Th | 0 | 0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 12,296 | 5,555 | 221.3% | |
Other income | Rs m | 184 | 103 | 178.2% | |
Total revenues | Rs m | 12,480 | 5,658 | 220.6% | |
Gross profit | Rs m | 3,247 | 602 | 539.3% | |
Depreciation | Rs m | 281 | 323 | 87.0% | |
Interest | Rs m | 8 | 3 | 261.9% | |
Profit before tax | Rs m | 3,142 | 379 | 828.4% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 847 | 114 | 745.5% | |
Profit after tax | Rs m | 2,295 | 266 | 863.8% | |
Gross profit margin | % | 26.4 | 10.8 | 243.7% | |
Effective tax rate | % | 27.0 | 30.0 | 90.0% | |
Net profit margin | % | 18.7 | 4.8 | 390.2% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 11,713 | 3,230 | 362.7% | |
Current liabilities | Rs m | 6,791 | 826 | 822.4% | |
Net working cap to sales | % | 40.0 | 43.3 | 92.5% | |
Current ratio | x | 1.7 | 3.9 | 44.1% | |
Inventory Days | Days | 263 | 37 | 711.7% | |
Debtors Days | Days | 343 | 504 | 68.2% | |
Net fixed assets | Rs m | 10,617 | 2,781 | 381.7% | |
Share capital | Rs m | 166 | 134 | 124.2% | |
"Free" reserves | Rs m | 7,265 | 4,470 | 162.5% | |
Net worth | Rs m | 7,431 | 4,603 | 161.4% | |
Long term debt | Rs m | 0 | 387 | 0.0% | |
Total assets | Rs m | 22,330 | 6,011 | 371.5% | |
Interest coverage | x | 409.1 | 130.0 | 314.6% | |
Debt to equity ratio | x | 0 | 0.1 | 0.0% | |
Sales to assets ratio | x | 0.6 | 0.9 | 59.6% | |
Return on assets | % | 10.3 | 4.5 | 230.7% | |
Return on equity | % | 30.9 | 5.8 | 535.1% | |
Return on capital | % | 42.4 | 7.7 | 553.4% | |
Exports to sales | % | 0 | 0 | - | |
Imports to sales | % | 13.1 | 0 | - | |
Exports (fob) | Rs m | NA | NA | - | |
Imports (cif) | Rs m | 1,605 | NA | - | |
Fx inflow | Rs m | 1,465 | 0 | - | |
Fx outflow | Rs m | 1,605 | 0 | - | |
Net fx | Rs m | -140 | 0 | - |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 2,360 | 366 | 644.3% | |
From Investments | Rs m | -215 | -508 | 42.3% | |
From Financial Activity | Rs m | -985 | -6 | 17,336.3% | |
Net Cashflow | Rs m | 1,160 | -220 | -526.4% |
Indian Promoters | % | 0.0 | 41.8 | - | |
Foreign collaborators | % | 51.8 | 0.0 | - | |
Indian inst/Mut Fund | % | 20.0 | 1.5 | 1,349.3% | |
FIIs | % | 6.2 | 1.5 | 421.6% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 48.2 | 58.2 | 82.7% | |
Shareholders | 56,778 | 19,913 | 285.1% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare PROCTER & GAMBLE HEALTH With: DIVIS LABORATORIES CIPLA SUN PHARMA DR. REDDYS LAB ZYDUS LIFESCIENCES
No comparison is complete without understanding how the stock prices have performed over a period of time.
Here's a brief comparison:
Period | Procter & Gamble Health | VENUS REMEDIES | S&P BSE HEALTHCARE |
---|---|---|---|
1-Day | -0.54% | 2.20% | -1.23% |
1-Month | -4.02% | 2.84% | 1.07% |
1-Year | -1.41% | 65.24% | 50.86% |
3-Year CAGR | -9.57% | 3.19% | 14.38% |
5-Year CAGR | 4.41% | 58.13% | 19.01% |
* Compound Annual Growth Rate
Here are more details on the Procter & Gamble Health share price and the VENUS REMEDIES share price.
Moving on to shareholding structures...
The promoters of Procter & Gamble Health hold a 51.8% stake in the company. In case of VENUS REMEDIES the stake stands at 41.8%.
To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of Procter & Gamble Health and the shareholding pattern of VENUS REMEDIES.
Finally, a word on dividends...
In the most recent financial year, Procter & Gamble Health paid a dividend of Rs 95.0 per share. This amounted to a Dividend Payout ratio of 68.7%.
VENUS REMEDIES paid Rs 0.0, and its dividend payout ratio stood at 0.0%.
You may visit here to review the dividend history of Procter & Gamble Health, and the dividend history of VENUS REMEDIES.
For a sector overview, read our pharmaceuticals sector report.
It was indeed a volatile trading session for Indian share markets yesterday.